Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523271 | 0.80 | PDE2A (0.45) | PDE2AALDH1A1PDK2KCNK3KCNK9 | |
| SCHEMBL27439645 | 0.79 | TRPA1 (0.48) | PDE2AALDH1A1PDK2KCNK3KCNK9 | |
| SCHEMBL130864 | 0.79 | ENPP2 (0.48) | ALDH1A1TRPA1PTGS1CACNA1C | |
| SCHEMBL30581674 | 0.79 | ENPP2 (0.48) | ALDH1A1TRPA1PTGS1CACNA1C | |
| SCHEMBL263459 | 0.77 | PDE2A (0.40) | PDE2AKCNK3KCNK9EPHX2 | |
| SCHEMBL14237419 | 0.77 | GPR3 (0.39) | PDE2AALDH1A1KCNK3KCNK9EPHX2 | |
| SCHEMBL15269928 | 0.77 | PDE2A (0.36) | PDE2AALDH1A1TYRAPPGAA | |
| SCHEMBL2662343 | 0.77 | PDE2A (0.62) | PDE2ACACNA1HEPHX2 | |
| SCHEMBL13523269 | 0.77 | PDE2A (0.43) | PDE2AALDH1A1PDK2KCNK3KCNK9 | |
| SCHEMBL12775740 | 0.77 | TRPA1 (0.37) | ALDH1A1TRPA1PTGS1CACNA1CTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | PDE2A 2617/4885ALDH1A1 3887/4885PDK2 3687/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | PDE2A 2617/4885ALDH1A1 3887/4885PDK2 3687/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | PDE2A 2617/4885ALDH1A1 3887/4885PDK2 3687/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | PDE2A 2617/4885ALDH1A1 3887/4885PDK2 3687/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | PDE2A 2617/4885ALDH1A1 3887/4885PDK2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.